Aprea Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Aprea Therapeutics (NASDAQ:APRE) reported Q4 earnings with an EPS of $-0.92, missing estimates by -19.0% and a revenue increase of $14 thousand from the previous year. Last quarter, the company beat EPS estimates which was followed by a 5.0% drop in share price.
March 26, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aprea Therapeutics reported a Q4 EPS of $-0.92, missing estimates by -19.0%, with a slight revenue increase from the previous year.
The miss on estimated earnings by -19.0% is likely to negatively impact investor sentiment, especially considering the historical context where a previous earnings beat was followed by a 5.0% drop in share price. This pattern suggests that even positive surprises have not sustained positive momentum for the stock, indicating a potentially stronger negative reaction to missed expectations.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100